Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.

27/02/2025

GMT Eight

Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.

FIRST PACIFIC(00142): PLDT INC. Net income attributable to equity holders in 2024 amounted to 32.307 billion pesos, an increase of 21.39% year-on-year.

HK Stock Market Move | GALAXY ENT (00027) rose over 3% in the afternoon, with a 28% year-on-year increase in net profit. A final dividend of 0.5 Hong Kong dollars will be paid.

Contact: contact@gmteight.com

Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.

RECOMMEND

BeiGene (06160) provides financial guidance for the first time: It is expected to achieve positive operating profit in 2025.

CHONGQING M&E (02722) proposes to purchase 100% equity of Chongqing Panlian Transmission Technology for 35.6212 million yuan.

TIMELESS (08028) plans to raise approximately HKD 29.1 million through a 2-for-1 rights issue.